Medical Condition News

RSS

Two Ottawa researchers take innovative approaches to improve virus-based cancer therapy

Two Ottawa researchers are taking innovative approaches to improving virus-based cancer therapy with new funding from the Canadian Cancer Society.

26 Jul 2012

Study finds disparities in the assessment of patients for kidney transplant

Young black patients and patients without private health insurance are less likely to be assessed for a kidney transplant when they start dialysis, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society of Nephrology (CJASN).

26 Jul 2012

Molecular explanation for increased susceptibility to intestinal inflammation in malnutrition

More than one billion people in poor countries are starving, and malnutrition remains a major problem even in rich countries, making it a leading cause of death in the world. For over a hundred years, doctors have known that a lack of protein in the diet or low levels of amino acids, the building blocks of proteins, can lead to symptoms like diarrhoea, inflamed intestines and other immune system disorders, which weaken the body and can be fatal. However, the molecular mechanism which explains how malnutrition causes such severe symptoms has been largely unexplored.

26 Jul 2012

AAQ chemical temporarily restores vision in blind mice

A team of University of California, Berkeley, scientists in collaboration with researchers at the University of Munich and University of Washington in Seattle has discovered a chemical that temporarily restores some vision to blind mice, and is working on an improved compound that may someday allow people with degenerative blindness to see again.

26 Jul 2012

Bio-Path initiates enrollment in fourth cohort of Liposomal Grb-2 Phase I trial for blood cancers

Bio-Path Holdings, Inc., a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced that it has begun enrolling patients into the fourth dosage cohort in its Phase I clinical trial of its lead product candidate, BP-100.1.01 (Liposomal Grb-2), which is being evaluated as a systemic treatment for blood cancers including acute myeloid leukemia (AML), chronic myelogenous leukemia (CML), acute lymphoblastic leukemia (ALL) and myelodysplastic syndrome (MDS).

26 Jul 2012

Follow-up exams for patients with celiac disease are often inadequate and highly variable

Follow-up exams for patients with celiac disease are often inadequate and highly variable, according to a new study in Clinical Gastroenterology and Hepatology, the official clinical practice journal of the American Gastroenterological Association (AGA).

26 Jul 2012

Consumption of alcohol mixed with energy drinks can lead to casual sex among college-age adults

A new study from the University at Buffalo's Research Institute on Addictions (RIA) has found a link between the consumption of caffeinated energy drinks mixed with alcohol and casual -- often risky -- sex among college-age adults.

26 Jul 2012

Female stroke patients more affected in all quality of life domains than males

Having a stroke or mini stroke has a much more profound effect on women than men when it comes to their quality of life, according to research published in the August issue of the Journal of Clinical Nursing.

26 Jul 2012

Multi-center clinical trial results demonstrate safety and efficacy of carfilzomib for multiple myeloma

Researchers from John Theurer Cancer Center at HackensackUMC, one of the nation's 50 best hospitals for cancer, played leading roles in three separate multi-center studies with the new proteasome inhibitor carfilzomib published in Blood, a major peer-reviewed scientific journal.

26 Jul 2012

Diabetic women more likely to report low overall sexual satisfaction

Women with diabetes are just as likely to be interested in, and engage in, sexual activity as non-diabetic women, but they are much more likely to report low overall sexual satisfaction, according to a UCSF study.

26 Jul 2012

FDA grants priority review to GSK’s Promacta sNDA for treatment of thrombocytopenia

Ligand Pharmaceuticals Incorporated today announced that its partner GlaxoSmithKline has been granted priority review from the US Food and Drug Administration for the supplemental new drug application for Promacta to treat thrombocytopenia in adult patients with chronic hepatitis C virus (HCV) infection.

26 Jul 2012

AHAF announces glaucoma and macular degeneration research grants

The American Health Assistance Foundation, a nonprofit organization with a history of funding breakthrough research on age-related vision diseases, announced today that it has awarded 21 new grants totaling $2.1 million to scientists worldwide who are studying glaucoma and macular degeneration. The two conditions are the leading causes of irreversible blindness in the world.

26 Jul 2012

ImmunoCellular receives FDA IND clearance for ICT-121 Phase I trial in glioblastoma multiforme

ImmunoCellular Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has given clearance to a physician sponsored investigative new drug (IND) application to initiate a Phase I clinical trial of ICT-121, IMUC's novel dendritic-cell-based vaccine targeting CD-133, an antigen that is highly expressed by multiple solid tumors.

26 Jul 2012

Bard completes enrollment in Lutonix DCB clinical trial for peripheral arterial disease

C. R. Bard, Inc. today announced that its Lutonix technology center completed patient enrollment into its global, multicenter LEVANT 2 randomized clinical trial.

26 Jul 2012

Vmersion-Health introduces Gluco-Share app for people with diabetes

Vmersion-Health introduces Gluco-Share, a mobile smart device application that connects people living with diabetes with their family and friends through a private and secure social media network. The Gluco-Share app is a free download available at the Apple iTunes store.

26 Jul 2012

Jennerex initiates JX-594 Phase 2 trial in advanced hepatocellular carcinoma

Jennerex, Inc., a private, clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic immunotherapies, today announced that the first patient has been treated in a Phase 2 clinical trial of intravenous treatment with JX-594 for patients with advanced hepatocellular carcinoma (HCC), or liver cancer, who have not received treatment with sorafenib—the current standard of care for this patient population.

26 Jul 2012

Miriam researchers encourage physicians to inquire about ED symptoms in young, middle-aged men

Although erectile dysfunction (ED) has been shown to be an early warning sign for heart disease, some physicians - and patients - still think of it as just as a natural part of "old age." But now an international team of researchers, led by physicians at The Miriam Hospital, say it's time to expand ED symptom screening to include younger and middle-aged men.

26 Jul 2012

Roche Diabetes Care announces availability of new ACCU-CHEK Nano SmartView System

Roche Diabetes Care, makers of ACCU-CHEK products and services, is pleased to announce the availability of the new, user-friendly ACCU-CHEK Nano SmartView System.

26 Jul 2012

Census Bureau releases report on disability status in the U.S.

About 56.7 million people ─ 19 percent of the population ─ had a disability in 2010, according to a broad definition of disability, with more than half of them reporting the disability was severe, according to a comprehensive report on this population released today by the U.S. Census Bureau.

26 Jul 2012

CytRx commences aldoxorubicin plus doxorubicin Phase 1b trial in advanced solid tumors

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced the initiation of a Phase 1b clinical trial to determine the maximum tolerated dose and to evaluate preliminary efficacy of aldoxorubicin (formerly INNO-206) administered in combination with the commonly used chemotherapeutic agent doxorubicin in patients with advanced solid tumors who have failed other therapies.

26 Jul 2012

Medical Condition News

Two Ottawa researchers take innovative approaches to improve virus-based cancer therapy

Study finds disparities in the assessment of patients for kidney transplant

Molecular explanation for increased susceptibility to intestinal inflammation in malnutrition

AAQ chemical temporarily restores vision in blind mice

Bio-Path initiates enrollment in fourth cohort of Liposomal Grb-2 Phase I trial for blood cancers

Follow-up exams for patients with celiac disease are often inadequate and highly variable

Consumption of alcohol mixed with energy drinks can lead to casual sex among college-age adults

Female stroke patients more affected in all quality of life domains than males

Multi-center clinical trial results demonstrate safety and efficacy of carfilzomib for multiple myeloma

Diabetic women more likely to report low overall sexual satisfaction

FDA grants priority review to GSK’s Promacta sNDA for treatment of thrombocytopenia

AHAF announces glaucoma and macular degeneration research grants

ImmunoCellular receives FDA IND clearance for ICT-121 Phase I trial in glioblastoma multiforme

Bard completes enrollment in Lutonix DCB clinical trial for peripheral arterial disease

Vmersion-Health introduces Gluco-Share app for people with diabetes

Jennerex initiates JX-594 Phase 2 trial in advanced hepatocellular carcinoma

Miriam researchers encourage physicians to inquire about ED symptoms in young, middle-aged men

Roche Diabetes Care announces availability of new ACCU-CHEK Nano SmartView System

Census Bureau releases report on disability status in the U.S.

CytRx commences aldoxorubicin plus doxorubicin Phase 1b trial in advanced solid tumors

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Latest News